	PMID	PT	OT	MH	SI	TI	GR
0	32934882	Journal Article;Research Support, NonU.S. Gov't;Research Support, U.S. Gov't, NonP.H.S.;Review	O  NNLM;*Dendritic cells;*epacadostat;*immune checkpoint blockers;*indoximod;*navoximod	DA 2020/09/17 06:01		Trial watch: IDO inhibitors in cancer therapy.	
1	32497632	Journal Article;Review		Aminoquinolines/therapeutic use;AntiBacterial Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/*isolation & purification;COVID19;COVID19 Vaccines;Coronavirus Infections/*drug therapy/prevention & control/virology;Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;Viral Vaccines/administration & dosage;DA 2020/08/25 06:00		Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical 	
2	32687696	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*antiinflammatory drugs;*antiviral drugs;*direct acting antivirals;*hosttargeted approaches;*repurposing;*small molecule inhibitors	Animals;AntiInflammatory Agents/therapeutic use;Antiviral Agents/*therapeutic use;Betacoronavirus/*drug effects/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/immunology/virology;*Drug Repositioning;Humans;Inflammation/immunology/prevention & control/virology;Pandemics;Pneumonia, Viral/*drug therapy/immunology/virology;SARSCoV2;Virus Replication/drug effects;DA 2020/09/24 06:00		Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.	
3	32814759	Journal Article;Research Support, NonU.S. Gov't		Animals;Antiviral Agents/pharmacology;Betacoronavirus/*physiology;COVID19;Cell Death/drug effects;Chlorocebus aethiops;Coronavirus Infections/*metabolism/virology;Drug Evaluation, Preclinical/*methods;Hydroxychloroquine/pharmacology;Imatinib Mesylate/pharmacology;Lysosomes/drug effects;Pandemics;Pneumonia, Viral/*metabolism/virology;Protein Kinase Inhibitors/pharmacology;RNA, Viral/drug effects;SARSCoV2;Vero Cells;Viral Load/drug effects;Virus Replication/*drug effects;DA 2020/09/02 06:00		On-target versus off-target effects of drugs inhibiting the replication of 	
4	32717568	Journal Article;Review	O  NNLM;*Chloroquine;*Coronavirus;*Lopinavir;*Remdesivir;*Ribavirin;*Ritonavir;*SARSCoV2	Animals;AntiBacterial Agents/administration & dosage/metabolism;Antibodies, Monoclonal, Humanized/administration & dosage/metabolism;Antimalarials/administration & dosage/metabolism;Antiviral Agents/*administration & dosage/metabolism;COVID19/*drug therapy/metabolism;Clinical Trials as Topic/methods;Cytochrome P450 CYP3A Inhibitors/administration & dosage/metabolism;Drug Approval/*methods;Drug Therapy, Combination;Humans;Hydroxychloroquine/administration & dosage/metabolism;SARSCoV2/*drug effects/metabolism;United States/epidemiology;DA 2020/12/29 06:00		FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) 	
5	33549625	Comment;Letter		Amides;*COVID19;Humans;Imatinib Mesylate/therapeutic use;Pyrazines;SARSCoV2;Treatment Outcome;DA 2021/05/01 06:00		Early clinical experience with imatinib in COVID-19: Searching for a dual effect.	
6	33391502	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*COVID19;*SARSCoV2;*cancer;*comorbidity;*coronaviruses;*inflammation	Antineoplastic Agents/pharmacology/*therapeutic use;COVID19/*drug therapy/epidemiology/immunology/virology;Comorbidity;Drug Repositioning;Genome, Viral/genetics;Humans;Neoplasms/*drug therapy/epidemiology;Pandemics/prevention & control;SARSCoV2/*genetics/immunology;Signal Transduction/drug effects/genetics/immunology;DA 2021/01/13 06:00		COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges.	K22 CA197074/CA/NCI NIH HHS/United States;P30 CA036727/CA/NCI NIH HHS/United States;1K22CA197074/CA/NCI NIH HHS/United States
7	33426509	Journal Article	O  NNLM;Drugs;HighPerformance Computing in Bioinformatics;Structural Biology;Virology	DA 2021/01/12 06:01		A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual 	R01 CA200913/CA/NCI NIH HHS/United States;R01 GM136859/GM/NIGMS NIH HHS/United States
8	33428075	Journal Article;Review	O  NNLM;Bone marrow;CCN2;CTGF;Connective tissue growth factor;Hematopoiesis;Leukemogenesis	DA 2021/01/12 06:01		CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, 	
9	32971210	Journal Article	O  NNLM;CMap;COVID19 drug;Network proximity;OpenVigil;Pharmacovigilance;Side effect	Antineoplastic Agents/*adverse effects/therapeutic use;Antiviral Agents/*adverse effects/therapeutic use;Betacoronavirus/drug effects;COVID19;Clinical Trials as Topic;Coronavirus Infections/*drug therapy;Humans;Immunologic Factors/*adverse effects/therapeutic use;Pandemics;*Pharmacovigilance;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/10/22 06:00		Comprehensive assessment of side effects in COVID-19 drug pipeline from a network 	
10	32550705	Journal Article;Review	O  NNLM;*COVID19 diagnostic testing [Supplementary Concept];*Patients;*Therapeutics	Betacoronavirus;Biomedical Research/*trends;COVID19;Coronavirus Infections/*therapy;Humans;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;DA 2020/07/24 06:00		Treatment and research lines for the patient with COVID-19. What do we have and 	
11	32375142	Editorial		Adrenal Cortex Hormones/adverse effects;Bone Marrow Transplantation;COVID19/*complications/drug therapy/epidemiology;China/epidemiology;Cohort Studies;EvidenceBased Medicine;Hematologic Neoplasms/*complications/therapy;Hematology;Humans;Immunotherapy, Adoptive;Pandemics;Risk Factors;*SARSCoV2;DA 2021/04/02 06:00		Perspective: SARS-CoV-2, COVID-19 and Haematologists.	
12	32546018	Journal Article;Review	O  NNLM;*COVID19;*Favipiravir;*acute respiratory distress syndrome;*chloroquine;*interferons;*nucleocapsid protein;*spike protein;*treatment	Antibodies, Monoclonal/therapeutic use;Antiviral Agents/*therapeutic use;*Betacoronavirus/chemistry/genetics/physiology;COVID19;Coronavirus Infections/complications/*drug therapy/epidemiology;*Drug Discovery;Humans;Pandemics;Pneumonia, Viral/complications/*drug therapy/epidemiology;SARSCoV2;Serine Endopeptidases/physiology;Serine Proteinase Inhibitors/therapeutic use;Virus Replication;DA 2020/08/04 06:00		The broad-spectrum antiviral recommendations for drug discovery against COVID-19.	
13	33200116	Preprint	O  NNLM;ACE2;COVID19 data;In silico;MPro;NSP16/NSP10;PLpro inhibitors;RdRP;SARSCoV 2;SARSCoV2 Small molecule inhibitor;Spike;TMPRSS2;computational biology;drug discovery;nsp10;nsp13;nsp14exonuclease;nsp16;nsp3 macrdomain;nsp5;nsp7;nsp8;nsp9;nucleoprotein;virtual screening	DA 2020/11/18 06:01		A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual 	
14	33156374	Journal Article;Review	O  NNLM;KIT inhibitors;Prognostic score;Systemic mastocytosis;Treatment	Cladribine/*therapeutic use;Humans;Interferons/*therapeutic use;Mast Cells/metabolism/pathology;Mastocytosis, Systemic/*drug therapy/metabolism/pathology;ProtoOncogene Proteins ckit/*antagonists & inhibitors/metabolism;DA 2021/01/27 06:00		Catching the clinical and biological diversity for an appropriate therapeutic 	21267/Associazione Italiana per la Ricerca sul Cancro/
15	32778962	Journal Article;Review	O  NNLM;COVID19;Coronavirus;MERSCoV;SARSCoV;SARSCoV2;antiviral therapy;kinase inhibitors;pharmacokinetics	Animals;Antiviral Agents/*therapeutic use;COVID19;Coronavirus Infections/*drug therapy;*Drug Repositioning;Humans;Pandemics;Pneumonia, Viral/*drug therapy;Protein Kinase Inhibitors/*therapeutic use;DA 2020/08/14 06:00		Repurposing of Kinase Inhibitors for Treatment of COVID-19.	Project Program Grant, NIH PO1CA66996/NH/NIH HHS/United States
16	33041814	Journal Article;Review	O  NNLM;COVID19 proposed therapy;Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2);convalescent plasma;pandemic;therapeutic challenges	DA 2020/10/13 06:01		Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future 	
17	32792167	Journal Article;Review	O  NNLM;*COVID19;*Clinical trials;*Corona pandemic;*Therapeutic;*Vaccination	COVID19/*drug therapy/virology;*Clinical Trials as Topic;Europe;Humans;SARSCoV2/*drug effects/pathogenicity;World Health Organization;DA 2020/12/30 06:00		Current updates on the European and WHO registered clinical trials of coronavirus 	
18	32623296	Journal Article;Review	O  NNLM;COVID19;Clinical trials;Drug safety;Drugdrug interactions;Drugrelated problems;HerbDrug interactions;Immune depression	Antineoplastic Agents/administration & dosage/adverse effects;Betacoronavirus/isolation & purification;COVID19;Clinical Trials as Topic/methods/standards;Coronavirus Infections/*drug therapy/*immunology/virology;Humans;Medical Oncology/methods/*standards;Neoplasms/*drug therapy/*immunology/virology;Pandemics;Pharmacy/methods/*standards;Pneumonia, Viral/*drug therapy/*immunology/virology;Practice Guidelines as Topic;SARSCoV2;DA 2020/07/30 06:00		Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage 	
19	33224405	Journal Article;Review	O  NNLM;Pharmacology;Prostacyclin;Prostaglandin;Pulmonary hypertension;Right heart failure;Therapeutics	DA 2020/11/24 06:01		Management of Pulmonary Arterial Hypertension.	
20	32992245	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Antiviral;*COVID19;*Coronavirus;*Repurposed drugs;*SARSCoV2	Antiviral Agents/chemistry/*therapeutic use;COVID19/immunology/*therapy;COVID19 Vaccines/*immunology;*Drug Repositioning;Humans;SARSCoV2/*drug effects/immunology;DA 2020/12/22 06:00		COVID-19 therapy: What weapons do we bring into battle?	
21	32999432	Letter;Research Support, N.I.H., Extramural		Antiviral Agents/*pharmacology;Betacoronavirus/*drug effects/growth & development/pathogenicity;COVID19;Caco2 Cells;Coronavirus Infections/drug therapy/virology;Drug Repositioning;Humans;Imatinib Mesylate/*pharmacology;Inhibitory Concentration 50;Niacinamide/*analogs & derivatives/pharmacology;Pandemics;Pneumonia, Viral/drug therapy/virology;Protein Kinase Inhibitors/*pharmacology;Pyrazoles/*pharmacology;Randomized Controlled Trials as Topic;SARSCoV2;Virus Internalization/drug effects;Virus Replication/drug effects;DA 2020/11/06 06:00	ClinicalTrials.gov/NCT04357613;ClinicalTrials.gov/NCT04394416;EudraCT/202000123610	Imatinib is not a potent anti-SARS-CoV-2 drug.	P30 CA042014/CA/NCI NIH HHS/United States;R01 CA178397/CA/NCI NIH HHS/United States;R01CA178397/U.S. Department of Health &amp; Human Services | NIH | National Cancer ;P30CA4201431/U.S. Department of Health &amp; Human Services | NIH | National Cancer 
22	32801052	Journal Article;Review		DA 2020/08/18 06:00		Derivatization and combination therapy of current COVID-19 therapeutic agents: a 	
23	33058394	Journal Article	O  NNLM;COVID19;SARSCoV2;antiviral drugs;therapeutic targets	Antiviral Agents/*pharmacology/therapeutic use;COVID19/*drug therapy/immunology/virology;Humans;Immune System Phenomena/*drug effects;SARSCoV2/*drug effects/immunology/metabolism/pathogenicity;DA 2020/12/19 06:00		SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.	Finance Code 001./Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/
24	32708302	Journal Article;Review	O  NNLM;NFκB pathway;anticancer;antiinflammatory;autoimmune disease;clinical trials;small molecules	AntiInflammatory Agents/*pharmacology;Antineoplastic Agents/*pharmacology;Drug Discovery/*methods;Humans;Ikappa B Kinase/antagonists & inhibitors/*metabolism;NFkappa B/antagonists & inhibitors/*metabolism;Proteasome Inhibitors/pharmacology;Signal Transduction/*drug effects/genetics;Ubiquitination/drug effects;DA 2021/03/05 06:00		Small Molecule NF-κB Pathway Inhibitors in Clinic.	NRFCRP17201702/National Research Foundation Singapore/
25	33162993	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Janus kinase 1/2;*chronic graftversushost disease;*hematopoietic stem cell transplantation;*immunotherapy;*tyrosine kinase inhibitors	DA 2020/11/10 06:00		New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current 	
26	32574699	Journal Article;Research Support, N.I.H., Extramural;Review		Animals;Antiviral Agents/pharmacology/*therapeutic use;Betacoronavirus/drug effects/isolation & purification;COVID19;Coronavirus Infections/*drug therapy/virology;Drug Discovery;Humans;OffLabel Use;Pandemics;Pneumonia, Viral/*drug therapy/virology;SARSCoV2;DA 2020/09/01 06:00		Discovering small-molecule therapeutics against SARS-CoV-2.	P01 HL107152/HL/NHLBI NIH HHS/United States;R01 HL090586/HL/NHLBI NIH HHS/United States;U01 CA241951/CA/NCI NIH HHS/United States;S10 RR027411/RR/NCRR NIH HHS/United States
27	33115543	Clinical Trial Protocol;Letter	O  NNLM;COVID19;Randomised controlled trial;SARSCoV;TKI;TKIinduced attenuation of vascular leak;TKIinduced prevention and treatment lung inflammation;imatinib;lysosomal sequestration;protocol;tyrosine kinase inhibitor;viral ABL1 signalling	Administration, Oral;Adult;*Betacoronavirus/drug effects/isolation & purification;COVID19;*Coronavirus Infections/diagnosis/drug therapy;Critical Care/methods;DoseResponse Relationship, Drug;DoubleBlind Method;Drug Monitoring;Female;Humans;*Imatinib Mesylate/administration & dosage/adverse effects;Male;*Pandemics;*Pneumonia, Viral/diagnosis/drug therapy;Protein Kinase Inhibitors/administration & dosage/adverse effects;Randomized Controlled Trials as Topic;SARSCoV2;Treatment Outcome;DA 2020/11/06 06:00	ClinicalTrials.gov/NCT04394416	Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured 	P30CA134274/CA/NCI NIH HHS/United States
28	33240091	Journal Article;Review	O  NNLM;COVID19;coronavirus;drug repositioning;drug repurposing;pandemic	DA 2020/11/27 06:01	ClinicalTrials.gov/NCT04244591;ClinicalTrials.gov/NCT04280705;ClinicalTrials.gov/NCT04304313;ClinicalTrials.gov/NCT04348695;ClinicalTrials.gov/NCT04359329;ClinicalTrials.gov/NCT04342663;ClinicalTrials.gov/NCT04321174	Challenges for Drug Repurposing in the COVID-19 Pandemic Era.	
29	33457170	Journal Article;Review	O  NNLM;Antivirals;COVID19;Drugs and COVID19;Nanothenology against COVID19;Natural products against COVID19;Vaccines against COVID19	DA 2021/01/19 06:01		Recent biotechnological advances as potential intervention strategies against 	
30	32702077	Preprint		DA 2020/07/24 06:01		Identification of new drug treatments to combat COVID19: A signature-based approach 	R01 MH107487/MH/NIMH NIH HHS/United States;R01 MH121102/MH/NIMH NIH HHS/United States
31	33232783	Journal Article;Review	O  NNLM;*Acute respiratory distress syndrome (ARDS);*COVID19;*Coronavirus;*Cytokine storm;*Dexamethasone;*Immune response;*SARSCoV2;*Treatment;*Vitamin D	Adaptive Immunity;Animals;COVID19/*immunology/*physiopathology;Clinical Trials as Topic;Cytokine Release Syndrome/immunology/prevention & control;Disease Management;Humans;Immunity, Innate;Immunologic Factors;Inflammation/immunology/prevention & control;SARSCoV2;Vitamin D/*immunology/therapeutic use;Zoonoses/immunology;DA 2021/01/05 06:00		Putative roles of vitamin D in modulating immune response and immunopathology 	
32	32923151	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*COVID19;*SARSCoV2;*cancer;*hydroxychloroquine;*immune checkpoint;*immunotherapy	Animals;Antineoplastic Combined Chemotherapy Protocols/*administration & ;Azithromycin/*administration & dosage/pharmacokinetics;COVID19/*drug therapy/immunology/virology;Cell Line, Tumor;Cisplatin/administration & dosage/pharmacokinetics;Clinical Trials, Phase II as Topic;Crizotinib/administration & dosage/pharmacokinetics;Disease Models, Animal;Drug Evaluation, Preclinical;Drug Interactions;Drug Therapy, Combination/methods;Female;France;Humans;Hydroxychloroquine/*administration & dosage/pharmacokinetics;Mice;Neoplasms/*drug therapy/immunology;Oxaliplatin/administration & dosage/pharmacokinetics;Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology;SARSCoV2/immunology/isolation & purification;DA 2020/09/15 06:01		Combination treatments with hydroxychloroquine and azithromycin are compatible with 	
33	32405780	Journal Article;Review	O  NNLM;drug therapy;novel coronavirus (2019nCoV);pneumonia;research progress	Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus;Biological Factors/therapeutic use;Biomedical Research/trends;COVID19;Coronavirus Infections/*drug therapy/therapy;Glucocorticoids/therapeutic use;Humans;Immunization, Passive;Medicine, Chinese Traditional;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/05/20 06:00		Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.	
34	32768564	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Lipid nanoparticles;*pHresponsive ionizable lipid;*siRNA	DA 2020/08/10 06:00		Recent advances in siRNA delivery mediated by lipid-based nanoparticles.	
35	33194671	Journal Article;Review	O  NNLM;cancer;coronavirus disease;coronavirus disease 2019;severe acute respiratory syndrome;severe acute respiratory syndrome coronavirus 2	DA 2020/11/17 06:01		Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and 	
36	33344513	Journal Article	O  NNLM;COVID19;cardiooncology;cytokine release syndrome;health disparities;inflammation;pandemic;right ventricle;telemedicine	DA 2020/12/22 06:01		Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.	R01 HL128240/HL/NHLBI NIH HHS/United States;R01 HL144098/HL/NHLBI NIH HHS/United States
37	32455629	Journal Article	O  NNLM;COVID19;SARSCoV2 coronavirus;drugs and medicinal substance repurposing;eriodictyol;estradiol;genomics;luteolin;mitigation approaches;quercetin;vitamin D	DA 2020/05/28 06:01		Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, 	
38	32545409	Journal Article;Review	O  NNLM;COVID19;head and neck cancer;head and neck squamous cell carcinoma;salivary gland cancer;skin cancer;thyroid cancer	DA 2020/06/18 06:01		The Evolution of Care of Cancers of the Head and Neck Region: State of the Science 	T32 DE017551/DE/NIDCR NIH HHS/United States;DDCF2015209/DDCF/Doris Duke Charitable Foundation/United States;DE016572/DE/NIDCR NIH HHS/United States;K08CA237858/CA/NCI NIH HHS/United States;CA243307/CA/NCI NIH HHS/United States;K08DE026542/DE/NIDCR NIH HHS/United States;K08 CA237858/CA/NCI NIH HHS/United States;GM008716/MH/NIMH NIH HHS/United States
39	33239864	Journal Article;Review	O  NNLM;COVID19;anticancer drugs;drugrepurposing	Antineoplastic Agents/*therapeutic use;Antiviral Agents/therapeutic use;COVID19/*drug therapy;Clinical Trials as Topic;*Drug Repositioning;Humans;DA 2020/12/15 06:00		Repurposing Anti-Cancer Drugs for COVID-19 Treatment.	P30 CA086862/CA/NCI NIH HHS/United States;T32 GM007337/GM/NIGMS NIH HHS/United States
40	32511912	Journal Article;Research Support, NonU.S. Gov't;Review		Amino Acid Sequence;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy;Drug Repositioning;Enzyme Inhibitors/therapeutic use;Humans;Immunity, Innate/drug effects;SARSCoV2/*drug effects;DA 2020/12/15 06:00		COVID-19: Drug Targets and Potential Treatments.	
41	32583086	Journal Article;Review	O  NNLM;COVID19;Complement;Eculizumab;Endothelium;HIF1alpha;Imatinib;SARSCoV;Thrombosis	Antibodies, Monoclonal, Humanized/administration & dosage;*Betacoronavirus;COVID19;Clinical Trials, Phase II as Topic/methods;Complement Inactivating Agents/*administration & dosage;Coronavirus Infections/drug therapy/*metabolism/pathology;Drug Delivery Systems/*methods;Endothelium, Vascular/drug effects/*metabolism/pathology;Humans;HypoxiaInducible Factor 1, alpha Subunit/antagonists & inhibitors/*metabolism;Imatinib Mesylate/administration & dosage;Pandemics/prevention & control;Pneumonia, Viral/drug therapy/*metabolism/pathology;ProteinTyrosine Kinases/antagonists & inhibitors/*metabolism;SARSCoV2;Signal Transduction/drug effects/physiology;DA 2020/07/15 06:00		COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential 	
42	33466743	Journal Article	O  NNLM;African natural products;SARSCoV2;SARSCoV2 inhibitors;coronavirus;molecular docking;molecular dynamics;virtual screening	Africa;Antiviral Agents/*chemistry/metabolism/*pharmacology;Bayes Theorem;Binding Sites;Biological Products/chemistry/metabolism/*pharmacology;Cheminformatics/methods;Coronavirus 3C Proteases/chemistry/*metabolism;Drug Evaluation, Preclinical;Fusidic Acid/chemistry/pharmacology;Ligands;Molecular Docking Simulation;Molecular Dynamics Simulation;Pentacyclic Triterpenes/chemistry/pharmacology;Protein Conformation;SARSCoV2/*drug effects;DA 2021/01/30 06:00		Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural 	
43	33050924	Clinical Trial, Phase III;Letter;Randomized Controlled Trial		Aged;Aged, 80 and over;Amides/therapeutic use;Antihypertensive Agents/therapeutic use;Antimalarials/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/*genetics;COVID19;Coronavirus Infections/*drug therapy/epidemiology/virology;Drug Tolerance;Feasibility Studies;France/epidemiology;Hospitalization/trends;Humans;Hydroxychloroquine/therapeutic use;Imatinib Mesylate/therapeutic use;Luxembourg/epidemiology;Outpatients/*statistics & numerical data;Pandemics;Pneumonia, Viral/*drug therapy/epidemiology/virology;Protein Kinase Inhibitors/therapeutic use;Pyrazines/therapeutic use;Risk Reduction Behavior;SARSCoV2;Telmisartan/therapeutic use;Therapies, Investigational/*statistics & numerical data;Treatment Outcome;DA 2020/11/04 06:00	ClinicalTrials.gov/NCT04356495	Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A 	NA/Université de Bordeaux/;NA/INSERM/;NA/Agence Nationale de la Recherche/;NA/Ministère de la Santé/;NA/EIT Health/
44	33244300	Journal Article	O  NNLM;COVID19;acute lung injury;cancer;cytokine release syndrome;multiorgan dysfunction;pneumonia;sepsis	DA 2020/11/28 06:01	ClinicalTrials.gov/NCT03680105	Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits 	
45	32468014	Journal Article;Review		Angiotensin II Type 1 Receptor Blockers/classification/therapeutic use;AngiotensinConverting Enzyme 2;Betacoronavirus/*drug effects/pathogenicity/physiology;Bromhexine/pharmacology/therapeutic use;COVID19;Chlorpromazine/pharmacology/therapeutic use;Clinical Trials as Topic/methods;Coronavirus Infections/*drug therapy/epidemiology/mortality;Diminazene/pharmacology/therapeutic use;*Drug Repositioning/methods/standards/trends;Gabexate/analogs & derivatives/pharmacology/therapeutic use;Humans;Pandemics;PeptidylDipeptidase A/chemistry/metabolism/therapeutic use;Pneumonia, Viral/*drug therapy/epidemiology/mortality;Receptor, Angiotensin, Type 1/metabolism;Recombinant Proteins/chemistry/therapeutic use;SARSCoV2;Signal Transduction/drug effects;Virus Internalization/*drug effects;DA 2020/07/02 06:00		Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights 	
46	33131530	Journal Article	O  NNLM;*COVID19;*Candidate drugs;*Infection pathways;*Interactome;*Prophylaxis agents;*Proteome;*SARSCoV2;*Transcriptome	*Antiviral Agents/chemistry/pharmacokinetics/therapeutic use;*Betacoronavirus/genetics/metabolism;COVID19;*Coronavirus Infections/drug therapy/genetics/metabolism;*Databases, Genetic;*Drug Discovery;Humans;*Models, Biological;*Pandemics;*Pneumonia, Viral/drug therapy/genetics/metabolism;Proteomics;SARSCoV2;DA 2020/11/18 06:00		Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs 	
47	32387301	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Baricitinib;*Begelomab;*COVID19;*GVHD;*MAS;*Ruxolitinib;*TKIs;*Tocilizumab	Betacoronavirus/drug effects;COVID19;Coronavirus Infections/*drug therapy;Graft vs Host Disease/drug therapy;Hematology/*methods;Humans;Macrophage Activation Syndrome/drug therapy;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/07/01 06:00		The CoV-2 outbreak: how hematologists could help to fight Covid-19.	
48	32572174	Journal Article		Adrenal Cortex Hormones/therapeutic use;Anticoagulants/therapeutic use;Antineoplastic Agents/pharmacology/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/*immunology/physiopathology/virology;Drug Repositioning/*methods;Humans;Immunologic Factors/therapeutic use;Inflammation/drug therapy;Interleukin6/antagonists & inhibitors;Pandemics;Pneumonia, Viral/*drug therapy/*immunology/physiopathology/virology;Programmed Cell Death 1 Receptor/antagonists & inhibitors;Protein Kinase Inhibitors/therapeutic use;SARSCoV2;Treatment Outcome;Vascular Endothelial Growth Factor A/antagonists & inhibitors;DA 2020/09/22 06:00		Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, 	
49	33125946	Journal Article;Review	O  NNLM;*Anticancer drugs;*COVID19;*Repurposing;*SARSCoV2	Antineoplastic Agents/*administration & dosage;Antiviral Agents/administration & dosage;COVID19/*drug therapy/virology;*Drug Repositioning;Humans;Pandemics;SARSCoV2/*drug effects;DA 2021/01/05 06:00		Repurposing anticancer drugs for the management of COVID-19.	
50	32654986	Journal Article	O  NNLM;Chronic myeloproliferative neoplasms;Novel coronavirus;SARSCoV2 pandemic	DA 2020/07/14 06:01		Guidelines for therapy of patients with chronic myeloproliferative neoplasms during 	
51	32991900	Journal Article;Review	O  NNLM;COVID19;Global pandemic;Investigational drugs;SARSCoV2;Vaccine development;Virus mechanism	Antiviral Agents/therapeutic use;COVID19/drug therapy/immunology/*therapy;*Clinical Trials as Topic;Humans;SARSCoV2/drug effects/immunology/physiology;Viral Vaccines/immunology;DA 2020/12/18 06:00		Novel insights into the treatment of SARS-CoV-2 infection: An overview of current 	R01 AI050875/AI/NIAID NIH HHS/United States;R21 AI121700/AI/NIAID NIH HHS/United States
52	33510484	News		Antibodies, Monoclonal/therapeutic use;Biological Products/*therapeutic use;COVID19/drug therapy;Cell and TissueBased Therapy;Drug Approval;Humans;Immunoconjugates/therapeutic use;Internationality;Rare Diseases/drug therapy;United States;United States Food and Drug Administration;DA 2021/03/10 06:00		Refreshing the biologic pipeline 2020.	
53	33123014	Journal Article;Review	O  NNLM;antimicrobial therapy;coronavirus disease 2019;drug;severe acute respiratory syndrome coronavirus 2;supportive therapy;vaccine	DA 2020/10/31 06:01		Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial 	
54	33130550	Journal Article;MetaAnalysis;Systematic Review	O  NNLM;*COVID19;*Cancer treatment;*Chemotherapy;*Immunotherapy;*SARSCoV2;*Targeted therapy	Antineoplastic Agents/pharmacology/*therapeutic use;COVID19/*mortality;Female;Humans;Male;Neoplasms/*drug therapy/mortality/*virology;Pandemics;SARSCoV2/isolation & purification;Turkey/epidemiology;DA 2021/01/05 06:00		A systematic review and meta-analysis: the effect of active cancer treatment on 	
55	32713239	Journal Article;Research Support, N.I.H., Extramural;Review	O  NNLM;*COVID‐19;*cancer;*cardiac imaging;*cardio‐oncology;*targeted therapies	*Betacoronavirus;COVID19;Cardiovascular Diseases/*epidemiology;Comorbidity;Coronavirus Infections/*epidemiology;Global Health;Humans;*Medical Oncology;Neoplasms/*epidemiology;Pandemics;Pneumonia, Viral/*epidemiology;*Public Health;SARSCoV2;Survival Rate/trends;DA 2020/10/21 06:00		Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond.	P30 CA016058/CA/NCI NIH HHS/United States;K12 CA133250/CA/NCI NIH HHS/United States
56	33217987	Journal Article;Review	O  NNLM;Carbonic anhydrase;DNA;Gquadruplex;anticancer agents;bioactive heterocyclics;histone deacetylase;kinases;oxadiazoles;telomerase;tubulin	*Antineoplastic Agents/chemistry/therapeutic use;*Cytotoxins/chemistry/therapeutic use;*Drug Design;Humans;Neoplasms/*drug therapy/metabolism/pathology;*Oxadiazoles/chemistry/therapeutic use;DA 2021/03/05 06:00		Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds.	
57	32661214	Journal Article;Review		Adrenal Cortex Hormones/*therapeutic use;AngiotensinConverting Enzyme 2;Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects/immunology/pathogenicity;COVID19;Coronavirus Infections/*drug therapy/epidemiology/immunology/virology;Disease Progression;Drug Discovery;*Drug Repositioning;Gene Expression Regulation;HostPathogen Interactions/drug effects/genetics/immunology;Humans;Hydroxychloroquine/therapeutic use;Immunologic Factors/*therapeutic use;Molecular Docking Simulation;Molecular Targeted Therapy/methods;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology;SARSCoV2;Signal Transduction/genetics/immunology;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/genetics/immunology;DA 2020/07/22 06:00		Drug targets for COVID-19 therapeutics: Ongoing global efforts.	
58	32671688	Journal Article;Review	O  NNLM;HCQ;Protease inhibitor;Remdesivir;SARSCoV2;Vaccines	Antiviral Agents/*therapeutic use;Betacoronavirus;COVID19;COVID19 Vaccines;Coronavirus Infections/epidemiology/prevention & control/*therapy;Humans;Pandemics/prevention & control;Pneumonia, Viral/epidemiology/*therapy;Protease Inhibitors/*therapeutic use;SARSCoV2;Viral Vaccines/*therapeutic use;DA 2020/09/15 06:00		Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 	R01AG042178, R01AG47812, R01NS105473, and AG060767/U.S. Department of Health and 
59	32539378	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review		Amino Acid Sequence;AngiotensinConverting Enzyme 2/chemistry/metabolism;AngiotensinConverting Enzyme Inhibitors/therapeutic use;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/prevention & control;Cathepsin L/antagonists & inhibitors;Cell Line;Humans;Protein Domains;SARSCoV2/*drug effects;Spike Glycoprotein, Coronavirus/antagonists & inhibitors;Virus Internalization/*drug effects;DA 2020/12/15 06:00		Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.	R01 AI150491/AI/NIAID NIH HHS/United States;R01 NS089435/NS/NINDS NIH HHS/United States
60	32722580	Journal Article;Review	O  NNLM;combined treatment;neoadjuvant treatment;soft tissue sarcoma	DA 2020/07/30 06:01		Neoadjuvant Treatment Options in Soft Tissue Sarcomas.	
61	32982751	Journal Article	O  NNLM;ClinicalTrials.gov;SARSCoV2;clinical trial;coronavirus disease 2019;registration	DA 2020/09/29 06:01		Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis.	
62	33169785	Journal Article		DA 2020/11/11 06:01		Abstract: Posters: 13th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 	
63	32961333	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't	O  NNLM;*AMY101;*Biomarkers;*C3 inhibition;*C5 blockade;*COVID19;*Drug efficacy;*Eculizumab;*Thromboinflammation	Antibodies, Monoclonal, Humanized/therapeutic use;Betacoronavirus/*pathogenicity;Biomarkers/blood;CReactive Protein/metabolism;COVID19;Cohort Studies;Complement Activation/drug effects;Complement C3/*antagonists & inhibitors/genetics/immunology;Complement C5/*antagonists & inhibitors/genetics/immunology;Complement Inactivating Agents/*therapeutic use;Coronavirus Infections/complications/*drug therapy/immunology/virology;Extracellular Traps/drug effects;Female;Gene Expression;Humans;Immunologic Factors/*therapeutic use;Interleukin6/metabolism;Male;Middle Aged;Neutrophils/drug effects/immunology/virology;Pandemics;Peptides, Cyclic/therapeutic use;Pneumonia, Viral/complications/*drug therapy/immunology/virology;Respiratory Distress Syndrome/complications/*drug therapy/immunology/virology;SARSCoV2;Severity of Illness Index;DA 2020/10/29 06:00		Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal 	P01 AI068730/AI/NIAID NIH HHS/United States
64	32873394	Journal Article;Review	O  NNLM;CRISPR;RNA therapy;gene editing;gene therapy;genodermatoses;skin;topical gene delivery	DA 2020/09/03 06:00		Gene Delivery to the Skin - How Far Have We Come?	
65	32437797	Journal Article;Review	O  NNLM;COVID19;Repurposing drugs;SARSCoV2;Spike proteins;Zoonotic origin	Animals;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*epidemiology/*therapy/virology;Pandemics/prevention & control;Pneumonia, Viral/*epidemiology/*therapy/virology;SARSCoV2;Zoonoses/epidemiology/therapy/virology;DA 2020/06/23 06:00		The current understanding and potential therapeutic options to combat COVID-19.	
66	33014780	Journal Article	O  NNLM;CML;COVID19;NanoString;TKIs;TTV;imatinib;immunity;nilotinib	DA 2020/10/06 06:01		Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic 	
67	33441124	Journal Article;Research Support, NonU.S. Gov't	O  NNLM;*Blood transcriptomics;*COVID19;*Coexpression analysis;*Drug repurposing;*Granulocytes;*Molecular disease phenotypes;*Neutrophils;*Stratification;*Transcriptome	Antiviral Agents/therapeutic use;COVID19/drug therapy/*pathology/virology;CaseControl Studies;DownRegulation;Drug Repositioning;Humans;Neutrophils/cytology/immunology/*metabolism;Phenotype;Principal Component Analysis;RNA/blood/chemistry/metabolism;Sequence Analysis, RNA;Severity of Illness Index;*Transcriptome;UpRegulation;DA 2021/01/22 06:00		Disease severity-specific neutrophil signatures in blood transcriptomes stratify 	
68	33535560	Journal Article;Review	O  NNLM;cellular mechanism;immunological response;sulforaphane	Animals;Cardiovascular Diseases/*drug therapy/immunology/pathology;Diabetes Mellitus, Type 2/*drug therapy/immunology/pathology;Humans;Immune System/*drug effects;Isothiocyanates/*therapeutic use;Neoplasms/*drug therapy/immunology/pathology;Protective Agents/*therapeutic use;Schizophrenia/*drug therapy/immunology/pathology;Sulfoxides/*therapeutic use;DA 2021/05/08 06:00		Potential of Sulforaphane as a Natural Immune System Enhancer: A Review.	1201418/Agencia Nacional de Investigación y Desarrollo (ANID)/
69	32581799	Journal Article;Review	O  NNLM;MAPK signaling;RAAS;cardiovascular burden;severe COVID19;signaling pathways	DA 2020/06/26 06:01		Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of 	
70	33025463	Journal Article;Research Support, NonU.S. Gov't;Review	O  NNLM;*Anticancer agents;*Atrial fibrillation;*COVID19;*Direct oral anticoagulants;*Drugdrug interactions;*QT prolongation	Antineoplastic Agents/*adverse effects;Arrhythmias, Cardiac/*chemically induced;Atrial Fibrillation/complications/*drug therapy;COVID19/complications/*drug therapy;Cytochrome P450 Enzyme Inhibitors/adverse effects;Cytochrome P450 Enzyme System;Drug Interactions;Factor Xa Inhibitors/*adverse effects;Hemorrhage/*chemically induced;Humans;Long QT Syndrome/chemically induced;Neoplasms/complications/*drug therapy;Thromboembolism/etiology/*prevention & control;DA 2020/12/15 06:00		The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug 	
71	32567371	Editorial		COVID19;Complementary Therapies/*methods;Coronavirus Infections/complications/*epidemiology/prevention & control;Delivery of Health Care, Integrated/*methods;Humans;Neoplasms/complications/*therapy;Pandemics/prevention & control;Pneumonia, Viral/complications/*epidemiology/prevention & control;Telemedicine/methods;DA 2020/07/01 06:00		Integrative Cancer Therapies: Learning From COVID-19.	
72	32585913	Journal Article;Review	O  NNLM;2019nCoV;COVID19;SARSCoV;SARSCoV2;antibodies;antivirals	DA 2020/06/27 06:01		SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug 	
73	32929317	Journal Article;Review	O  NNLM;Antiviral;COVID19;Cellular therapy;Drug;Immunotherapy;Pandemic	DA 2020/09/16 06:00		What are the drugs having potential against COVID-19?	
74	33532135	Journal Article;Review	O  NNLM;COVID19;Chinese Medicine;strategies;treatment	DA 2021/02/04 06:01		A Comprehensive Summary of the Knowledge on COVID-19 Treatment.	
75	32654006	Journal Article	O  NNLM;*Acute respiratory distress syndrome;*Acute respiratory failure;*Coronavirus;*Mesenchymal stromal cells;*Pharmacologic therapy	Antioxidants/therapeutic use;Ascorbic Acid/therapeutic use;COVID19/*drug therapy;Citrulline/therapeutic use;Drug Therapy/*trends;Glycoproteins/therapeutic use;Humans;Mesenchymal Stem Cells;Pandemics;Peptides, Cyclic/therapeutic use;Pyridones/therapeutic use;Pyrimidines/therapeutic use;Receptors, Tumor Necrosis Factor, Type I/antagonists & inhibitors/therapeutic use;Respiratory Distress Syndrome/*drug therapy;Steroids/therapeutic use;Trypsin Inhibitors/therapeutic use;DA 2020/12/29 06:00		Emerging pharmacological therapies for ARDS: COVID-19 and beyond.	MC_G1002460/MRC_/Medical Research Council/United Kingdom;MR/M009149/1/MRC_/Medical Research Council/United Kingdom
76	32513299	Clinical Trial Protocol;Letter	O  NNLM;Anluohuaxian;COVID19;Protocol;Pulmonary fibrosis;Randomised controlled trial	Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drugs, Chinese Herbal/adverse effects/*therapeutic use;Female;Humans;Lung/diagnostic imaging;Male;Middle Aged;Multicenter Studies as Topic;Outcome Assessment, Health Care;Pandemics;Pneumonia, Viral/*drug therapy;Prospective Studies;*Randomized Controlled Trials as Topic;SARSCoV2;Walking;Young Adult;DA 2020/07/01 06:00	ClinicalTrials.gov/NCT04334265	Efficacy and safety of Anluohuaxian in the treatment of patients with severe 	2017ZX10203202/China MegaProject for Infectious Diseases/;2013ZX10002005/China MegaProject for Infectious Diseases/;2016ZX09101065/China MegaProject for Innovative Drugs/
77	32317408	Journal Article;Review	O  NNLM;* COVID19;* drugs;* hostbased;* repurposing;* severe acute respiratory syndrome coronavirus 2;* virusbased;*Coronavirus	Antiviral Agents/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drug Discovery;*Drug Repositioning;Humans;Molecular Docking Simulation;Pandemics;Pneumonia, Viral/*drug therapy;Protease Inhibitors/therapeutic use;SARSCoV2;Viral Proteins/antagonists & inhibitors;DA 2020/05/07 06:00		Perspectives for repurposing drugs for the coronavirus disease 2019.	
78	32616710	Journal Article;Research Support, NonU.S. Gov't;Review		DA 2020/07/04 06:00		Overcoming cancer therapeutic bottleneck by drug repurposing.	
79	32081774	Journal Article;Review	O  NNLM;Antiviral drug;BSAAs;Broadspectrum antiviral agents;Drug discovery and development;Virus	Animals;*Antiviral Agents/therapeutic use;*Drug Development;*Drug Discovery;Humans;Virus Diseases/drug therapy;DA 2020/07/25 06:00		Discovery and development of safe-in-man broad-spectrum antiviral agents.	
80	32719749	Journal Article	O  NNLM;COVID19;CT scan;coronavirus;hematologic malignancies;hematology;polymerase chain reaction;screening	DA 2020/07/29 06:01		Screening Strategies for COVID-19 in Patients With Hematologic Malignancies.	
81	32817953	Preprint		DA 2020/08/21 06:01		Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in 	R35 GM119617/GM/NIGMS NIH HHS/United States
82	33123148	Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Review	O  NNLM;*GMCSF;*MCSF;*chemokines;*miRNAs;*multiple sclerosis;*myeloid cels;*nanoparticles	Animals;Cell Movement;Central Nervous System/*physiology;Cytokines/metabolism;Encephalomyelitis, Autoimmune, Experimental/*therapy;Humans;Mice;MicroRNAs/genetics;Multiple Sclerosis/*therapy;Myeloid Cells/*physiology;Nanoparticles;Neurogenic Inflammation/*therapy;DA 2021/06/01 06:00		Potential for Targeting Myeloid Cells in Controlling CNS Inflammation.	R01 NS062365/NS/NINDS NIH HHS/United States;R01 EB013198/EB/NIBIB NIH HHS/United States;R01 NS026543/NS/NINDS NIH HHS/United States;R01 NS099334/NS/NINDS NIH HHS/United States;R21 AI142059/AI/NIAID NIH HHS/United States
